Entities / Company
Leerink partners.
U.S. investment bank
- Reports this week
- 12
- Active events
- 8
- Connections
- 194
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Some support6 reports
-
A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Well supported7 reports
-
Leerink Partners provided coverage and price targets for Freenome on September 26, 2026.Some support1 report
-
Leerink Partners upgraded Gossamer Bio stock rating on September 26, 2026.Some support1 report
-
Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.Some support2 reports
-
Leerink partners issued an 'outperform' rating on Teva stock, while an insider sold shares of the company.Some support3 reports
-
Analyst firm Leerink partners raised the price target for Roivant based on share count forecast on August 13, 2025.Well supported4 reports1 development inside
-
An analyst firm has provided price target recommendations for Universal Health Services.Some support1 report
Earlier this month
-
Leerink Partners started coverage on ANI Pharmaceuticals shares.Some support2 reports
-
Analyst firm upgraded price objective on 10X Genomics stock.Some support1 report
-
Leerink raised its price target for UnitedHealth Group stock.Some support2 reports
-
Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.Some support1 report
-
Truist Financial and Leerink Partners raised price objectives for Eli Lilly and Company stock.Some support1 report
-
Kazia Therapeutics Limited is seeking joint bookrunning management and co-management for a proposed offering, with Leerink partners and Needham & Company involved.Some support15 reports1 development inside
One to three months ago
-
TD Cowen raised price targets for GoodRx stock.Some support1 report
-
Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.Some support1 report
-
Scribe Therapeutics completed its IPO, led by Leerink Partners, with major backing from Eli Lilly and Andreessen Horowitz.Some support2 reports
-
Leerink partners provided research reports on AirSculpt Technologies on August 17, 2026.Some support1 report
-
Leerink Partners cut price target on Stryker Corporation, and Norges Bank bought a new position in Stryker shares.Some support1 report
-
Cantor Fitzgerald and Leerink partners issued rating changes for Replimune Group, Inc. on July 13, 2026.Some support2 reports
-
Citigroup raised its rating on Innate Pharma stock, which trades on the Nasdaq exchange. Leerink Partners also upgraded the rating. MarketBeat aggregates the rating data.Some support1 report
-
Cantor Fitzgerald and Leerink Partners initiated analyst coverage on Avidity Biosciences on August 10, 2026.Some support3 reports
-
MarketBeat is providing consensus rating for Alamar Biosciences, and Leerink Partners and Bank of America have initiated coverage on the company.Some support1 report
-
Analyst coverage is influencing stock price targets for companies including Bank of America, Eli Lilly and Company, Leerink partners, and Cantor Fitzgerald.Some support9 reports6 developments inside
-
Halozyme's stock performance was mentioned in proximity to Leerink Partners on August 7, 2026.Some support1 report
-
LB Pharmaceuticals Inc is seeking institutional investment for a private placement, utilizing Leerink Partners as the placement agent, with BB Biotech as a key entity.Some support1 report1 development inside
-
Leerink partners began its role as the lead book-running manager for an offering on behalf of BlossomHill Therapeutics, Inc. on August 1, 2026.Some support1 report
-
Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.Well supported6 reports
-
Analyst downgrades are affecting Leerink partners' stock price, which is listed on the Nasdaq stock exchange.Some support2 reports
-
Leerink partners adjusted its rating and target price for Medtronic plc on July 31, 2026.Some support1 report
-
Scribe Therapeutics is based in Alameda, California, while Leerink Partners maintains an office in Boston, MA. The article also notes Goldman Sachs has an office in New York.Some support1 report
-
Leerink Partners raised price target for Thermo Fisher Scientific Inc. (TMO) on July 23, 2026.Some support2 reports
-
SpaceX's IPO was expected to top US deals, with Jack Bannister identified as senior managing director at Leerink Partners.Some support1 report
-
Leerink partners set a $152.00 target price on Encompass Health shares.Some support1 report
-
Veradermics, Incorporated is facing market challenges in the US, with analyst reports affecting its stock price.Some support3 reports
-
Arcus Biosciences' stock rating and price were influenced by analyst reports, and the company filed with the SEC regarding institutional purchases.Well supported6 reports
-
The Tennessee Department of Treasury bought a new position in stock, while Citigroup reaffirmed its 'outperform' rating and Leerink Partners set a $43.00 price objective.Some support1 report
-
The FDA granted premarket approval for the LungFX device for use with United Therapeutics, while Leerink partners maintained an Outperform rating on the company's shares.Some support2 reports
-
Berenberg Bank and Leerink Partners raised price targets for Eli Lilly and Company on July 8, 2026.Some support5 reports
-
Leerink partners provided research notes on the stock of CorMedix Inc. on July 2, 2026.Some support2 reports
-
Leerink partners evaluates Abivax drug safety data on July 1, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Morgan Stanley and Leerink partners provided buy ratings and target prices for AgomAb Therapeutics on June 29, 2026.Some support3 reports
-
Leerink partners maintained a Buy rating on Ardelyx on June 25, 2025.Speculative1 report1 development inside
-
Analyst firm reaffirmed rating on Ardelyx stock, while an insider sold company shares.Some support1 report
-
Cantor Fitzgerald and Leerink partners are acting as joint bookrunning managers for an offering involving a Swiss company, requiring an SEC filing.Some support2 reports
-
An analyst firm provided target price updates for Oruka Therapeutics, Inc. on June 6, 2026.Some support5 reports
-
Leerink partners and Truist Financial issued research reports, including buy ratings and price objective lifts, regarding Absci Corporation's stock.Some support2 reports
-
MarketBeat aggregates analyst ratings and Benzinga reports on ARS Pharmaceuticals, which saw Leerink Partners cut its price target to $24.00.Some support1 report
-
RBC Capital Markets and Leerink partners jointly manage the bookrunning of an offering starting June 1, 2026.Some support2 reports
-
Financial firms have issued buy ratings and price targets for Definium Therapeutics stock.Some support1 report
-
uniQure N.V. is pursuing a public offering and has appointed Leerink partners as the bookrunning manager, with filings made to the SEC since June 1, 2026.Some support1 report
-
Leerink Partners was appointed as the joint bookrunning manager for MoonLake Immunotherapeutics starting on June 1, 2026.Some support1 report
-
MarketBeat aggregated analyst ratings for Altimmune, Inc., while Leerink Partners began coverage of the stock.Some support1 report
-
Leerink, Truist, and Needham downgraded Centessa Pharmaceuticals shares, while Karen M. Anderson sold shares.Some support2 reports
-
Centessa Pharmaceuticals saw institutional investor filings and analyst downgrades on June 18, 2026.Some support1 report
-
Leerink Partners restated an outperform rating, and Cantor Fitzgerald restated an overweight rating regarding 3D Systems.Well supported4 reports
-
Leerink Partners dropped its price objective on Clover Health.Some support1 report
-
Granahan Investment Management trimmed its stake in AnaptysBio, Inc. and set a $90.00 target price on shares.Some support1 report
-
Leerink partners provided an 'outperform' rating on the shares of Structure Therapeutics on June 15, 2026.Some support1 report
-
Analyst firm Leerink partners lowered the price target on Medtronic stock on June 12, 2026.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Leerink partners this week
News at the entities that move Leerink partners most-
company TransactionalBoard approved a quarterly cash dividend increase on August 1, 2026.Moves Leerink partners
-
Nasdaq Shared contextApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Leerink partners
-
Intuitive Surgical Mentioned togetherMedtronic is ramping up its Hugo RAS system to compete with Intuitive Surgical, while its neuroscience unit faces competitive pressure from Stryker and Globus Medical.Moves Leerink partners
-
Cantor Fitzgerald OperationalAnalyst firm lowered price targets on Automatic Data Processing (ADP) stock on June 6, 2026.Moves Leerink partners
-
Illumina Mentioned togetherAnalysis suggests that both Moderna and Illumina stocks are currently overvalued.Moves Leerink partners
-
Guardant Health TransactionalEVANS welcomed Guardant Health as a sponsor for a coalition planning events across North America.Moves Leerink partners
Connections
The 40 strongest of 194, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
BrightSpring Health Services Operational
Leerink Partners provides financial analysis and acts as a bookrunner for BrightSpring Health Services' offerings.
-
Faisal Khurshid Structural
Faisal Khurshid is employed as an analyst at Leerink Partners.
-
company Transactional
Leerink partners and the company are jointly appointed as bookrunning managers for a financial offering.
-
Jack Bannister Structural
Jack Bannister serves as a senior managing director at Leerink Partners.
-
Aquestive (United States) Transactional
Leerink partners jointly managed a stock offering for Aquestive.
-
Incyte Transactional
Leerink partners increased its price objective regarding Incyte.
-
Scribe Therapeutics Operational
Leerink Partners actively influenced Scribe Therapeutics by leading its IPO and providing market ratings.
-
GoodRx Mentioned together
Leerink Partners provides financial research and price targets for GoodRx stock.
Show all 40 connections
-
Arrowhead Pharmaceuticals Mentioned together
Leerink partners issued a price target and rating for Arrowhead Pharmaceuticals.
-
UnitedHealth Group Mentioned together
Leerink partners provides financial analysis, including price targets and ratings, for UnitedHealth Group stock.
-
Nanobiotix Mentioned together
Leerink partners provides analyst ratings and price targets for Nanobiotix stock.
-
Medtronic plc Mentioned together
Leerink partners provides market research and analysis on Medtronic plc's stock performance.
-
Roivant Sciences (United States) Mentioned together
Leerink partners provides financial analysis and price targets for Roivant Sciences.
-
Halozyme Therapeutics Mentioned together
Leerink Partners functions as an analyst firm, providing market research reports and assessments on Halozyme Therapeutics.
-
Stryker Corporation Mentioned together
Leerink partners provides financial research and analyst coverage regarding Stryker Corporation's stock.
-
Intuitive Surgical Mentioned together
Leerink Partners provides financial analysis and bullish ratings on Intuitive Surgical.
-
Nasdaq Shared context
A company listed on the Nasdaq stock exchange.
-
Encompass Health Mentioned together
Leerink Partners provides financial analysis and sets price targets for Encompass Health.
-
Insmed Transactional
Leerink Partners acted as a joint book-running manager for Insmed during a financial offering.
-
Illumina Mentioned together
Leerink partners provides financial research reports and price targets regarding Illumina.
-
PROCEPT BioRobotics Mentioned together
Analysts from Leerink partners issue ratings and commentary that affect PROCEPT BioRobotics' valuation.
-
Edwards Lifesciences Operational
Leerink Partners provides market analysis, including rating changes and price targets, for Edwards Lifesciences.
-
United Therapeutics Mentioned together
Leerink Partners provides investment ratings and coverage on United Therapeutics stock.
-
Cantor Fitzgerald Operational
The two companies actively collaborate as joint bookrunning managers in financial transactions.
-
Doximity Operational
Leerink Partners actively influenced Doximity's market perception by decreasing its target price.
-
Guardant Health Transactional
Leerink partners issued a price objective rating on Guardant Health.
-
Kymera Therapeutics Transactional
Leerink Partners served as a joint book-running manager for Kymera Therapeutics.
-
MannKind Corporation Mentioned together
Leerink Partners provides financial ratings and price targets for MannKind Corporation.
-
Arcus Biosciences Operational
Leerink partners' analyst reports and target prices are observed to influence Arcus Biosciences' stock rating and price.
-
Teva Pharmaceutical Industries Ltd. Mentioned together
Leerink Partners provides financial coverage and ratings on Teva Pharmaceutical Industries Ltd. stock.
-
Vertex Pharmaceuticals Mentioned together
Leerink Partners, a boutique advisory firm, has initiated market coverage on Vertex Pharmaceuticals and advised companies in its ecosystem.
-
Thermo Fisher Scientific Inc. Mentioned together
Leerink Partners issued rating upgrades and price targets for Thermo Fisher Scientific, influencing market perception.
-
SpaceX Operational
The relationship is suggested to be competitive, with SpaceX expected to be a major player in the US market deals.
-
Clover Health Transactional
Leerink Partners issued a market report that included a dropped price objective for Clover Health.
-
Neurocrine Biosciences Mentioned together
Leerink Partners has provided analyst coverage, including raising the target price, for Neurocrine Biosciences.
-
Amneal Pharmaceuticals, Inc. Mentioned together
The relationship is based on shared market research coverage and analyst ratings.
-
Twist Bioscience Mentioned together
The relationship is characterized by shared market analyst coverage, specifically regarding price targets.
-
Bruker Mentioned together
Leerink Partners issued a price objective recommendation regarding Bruker.
-
Universal Health Services Mentioned together
Market analysts are providing price target recommendations for both companies.
-
Align Technology Mentioned together
Analyst coverage links the two companies through shared market sentiment and price target adjustments.
History
Events by the month they beganSeptember 2026
9 events- Leerink Partners provided coverage and price targets for Freenome on September 26, 2026.
- Leerink Partners upgraded Gossamer Bio stock rating on September 26, 2026.
- Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
- Leerink partners issued an 'outperform' rating on Teva stock, while an insider sold shares of the company.
- An analyst firm has provided price target recommendations for Universal Health Services.
- Leerink Partners started coverage on ANI Pharmaceuticals shares.
- Analyst firm upgraded price objective on 10X Genomics stock.
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
- Truist Financial and Leerink Partners raised price objectives for Eli Lilly and Company stock.
August 2026
11 events- Kazia Therapeutics Limited is seeking joint bookrunning management and co-management for a proposed offering, with Leerink partners and Needham & Company involved.
- TD Cowen raised price targets for GoodRx stock.
- Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.
- Leerink partners provided research reports on AirSculpt Technologies on August 17, 2026.
- Leerink Partners cut price target on Stryker Corporation, and Norges Bank bought a new position in Stryker shares.
- Citigroup raised its rating on Innate Pharma stock, which trades on the Nasdaq exchange. Leerink Partners also upgraded the rating. MarketBeat aggregates the rating data.
- Cantor Fitzgerald and Leerink Partners initiated analyst coverage on Avidity Biosciences on August 10, 2026.
- MarketBeat is providing consensus rating for Alamar Biosciences, and Leerink Partners and Bank of America have initiated coverage on the company.
- Halozyme's stock performance was mentioned in proximity to Leerink Partners on August 7, 2026.
- Leerink partners began its role as the lead book-running manager for an offering on behalf of BlossomHill Therapeutics, Inc. on August 1, 2026.
- Analyst downgrades are affecting Leerink partners' stock price, which is listed on the Nasdaq stock exchange.
July 2026
16 events- Scribe Therapeutics completed its IPO, led by Leerink Partners, with major backing from Eli Lilly and Andreessen Horowitz.
- Cantor Fitzgerald and Leerink partners issued rating changes for Replimune Group, Inc. on July 13, 2026.
- Analyst coverage is influencing stock price targets for companies including Bank of America, Eli Lilly and Company, Leerink partners, and Cantor Fitzgerald.
- LB Pharmaceuticals Inc is seeking institutional investment for a private placement, utilizing Leerink Partners as the placement agent, with BB Biotech as a key entity.
- Leerink partners adjusted its rating and target price for Medtronic plc on July 31, 2026.
- Scribe Therapeutics is based in Alameda, California, while Leerink Partners maintains an office in Boston, MA. The article also notes Goldman Sachs has an office in New York.
- Leerink Partners raised price target for Thermo Fisher Scientific Inc. (TMO) on July 23, 2026.
- SpaceX's IPO was expected to top US deals, with Jack Bannister identified as senior managing director at Leerink Partners.
- Leerink partners set a $152.00 target price on Encompass Health shares.
- Veradermics, Incorporated is facing market challenges in the US, with analyst reports affecting its stock price.
- Arcus Biosciences' stock rating and price were influenced by analyst reports, and the company filed with the SEC regarding institutional purchases.
- The Tennessee Department of Treasury bought a new position in stock, while Citigroup reaffirmed its 'outperform' rating and Leerink Partners set a $43.00 price objective.
- The FDA granted premarket approval for the LungFX device for use with United Therapeutics, while Leerink partners maintained an Outperform rating on the company's shares.
- Berenberg Bank and Leerink Partners raised price targets for Eli Lilly and Company on July 8, 2026.
- Leerink partners provided research notes on the stock of CorMedix Inc. on July 2, 2026.
- Leerink partners evaluates Abivax drug safety data on July 1, 2026.
Show 1 earlier month
June 2026
24 events- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.
- A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.
- Analyst firm Leerink partners raised the price target for Roivant based on share count forecast on August 13, 2025.
- Leerink raised its price target for UnitedHealth Group stock.
- Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.
- Morgan Stanley and Leerink partners provided buy ratings and target prices for AgomAb Therapeutics on June 29, 2026.
- Leerink partners maintained a Buy rating on Ardelyx on June 25, 2025.
- Analyst firm reaffirmed rating on Ardelyx stock, while an insider sold company shares.
- Cantor Fitzgerald and Leerink partners are acting as joint bookrunning managers for an offering involving a Swiss company, requiring an SEC filing.
- An analyst firm provided target price updates for Oruka Therapeutics, Inc. on June 6, 2026.
- Leerink partners and Truist Financial issued research reports, including buy ratings and price objective lifts, regarding Absci Corporation's stock.
- MarketBeat aggregates analyst ratings and Benzinga reports on ARS Pharmaceuticals, which saw Leerink Partners cut its price target to $24.00.
- RBC Capital Markets and Leerink partners jointly manage the bookrunning of an offering starting June 1, 2026.
- Financial firms have issued buy ratings and price targets for Definium Therapeutics stock.
- uniQure N.V. is pursuing a public offering and has appointed Leerink partners as the bookrunning manager, with filings made to the SEC since June 1, 2026.
- Leerink Partners was appointed as the joint bookrunning manager for MoonLake Immunotherapeutics starting on June 1, 2026.
- MarketBeat aggregated analyst ratings for Altimmune, Inc., while Leerink Partners began coverage of the stock.
- Leerink, Truist, and Needham downgraded Centessa Pharmaceuticals shares, while Karen M. Anderson sold shares.
- Centessa Pharmaceuticals saw institutional investor filings and analyst downgrades on June 18, 2026.
- Leerink Partners restated an outperform rating, and Cantor Fitzgerald restated an overweight rating regarding 3D Systems.
- Leerink Partners dropped its price objective on Clover Health.
- Granahan Investment Management trimmed its stake in AnaptysBio, Inc. and set a $90.00 target price on shares.
- Leerink partners provided an 'outperform' rating on the shares of Structure Therapeutics on June 15, 2026.
- Analyst firm Leerink partners lowered the price target on Medtronic stock on June 12, 2026.